HGEN - Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Humanigen (HGEN) perks 7% premarket after executing its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical, Inc. and KPM Tech Co., Ltd for development and commercialization rights to lenzilumab for COVID-19 for South Korea and the Philippines. Telcon and KPM Tech, both recently invested in HGEN June 2020 PIPE offering.Agreement provides Humanigen up to $20M in milestones and double-digit royalties on product sales. Telcon and KPM Tech will be responsible for gaining regulatory approval and subsequent commercialization of lenzilumab in its territories.

For further details see:

Humanigen executes lenzilumab licensing deal in Asia for COVID-19